<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<title>人民医院——科教管理</title>
<script language="javascript">
var tid=41 ;
var sid=41 ;
</script>
<meta name="keywords" content="医院，红十字，健康，专家，科研，教学，论文，研究生，学术，下载，获奖成果，进修，继续教育，住院医师
">
<link rel="stylesheet" type="text/css" href="/front/images/kygz.css">
</head>
<body>
<div class="wrapper">
    <div class="header">
        <div class="hea_up">
            <div class="logo"><img src="/front/images/ky_logo.jpg" width="455" height="127"></div>
            <div class="search">
                <form id="productSearch" method="post" action="/List/News" name="Search">
                <div class="ss_a">
                <input id="search_text" type="text" name="key">
                </div>
                <div class="ss_b"><img id="btnsearch" style="cursor:pointer;" src="/front/images/ss_anniu.jpg" width="49" height="25" border="0" onclick="if(Search.key.value==''){alert('请输入关键字!');}else{productSearch.submit();}">
                </div>
		</form>
            </div>
        </div>
        <div class="nav">
            <script type="text/javascript" src="/front/infor/js/31-0.js"></script>
        </div>
    </div>
    <div class="banner">
        <div class="ksdh">
            <ul>
            <li><a href="/front/../List/News/163.html">查询系统</a></li>
            <li><a href="/front/../content/detail/c242.html">GCP入口</a></li>
            <li><a href="javascript:window.open('/List/News/437');">医学伦理</a></li>
            </ul>
        </div>
    </div>
    <div class="main">
        <div class="zb_con">
            <div class="left_menu_bt">科技动态</div>    
	    <div class="left_menu_nr" id="leftmenu">
                <script src="/Execute/Module/52/0" type="text/javascript" ></script>
            </div>
        </div>
        <div class="right">
                 <div class="right_bt">
           <strong>您现在的位置：</strong>
           <a href="/front/../home/index.html">首页</a>>><a href='../../kjgl/index.html'>科教管理</a>>><a href='../../kjgl/index.html'>科研工作</a>>>科技动态
     </div>
     <div class="right_nr">
           <div class="xingfa_nr">
                 <div class="timu">我院眼科牵头组织实施国家“十三五”重大创新药IBI302项目临床试验
		 </div>
		 <p><p><p align="center"><font face="宋体" size="3"><br></font></p><p align="center"><font face="宋体" size="3"><img alt="" src="/front/../upload/images/201808/23135546.jpg" border="0" vspace="0" hspace="-1"></font></p><p><br></p><p align="center"><font face="宋体" size="3"><img alt="" src="/front/../upload/images/201808/29083139.jpg" border="0" vspace="0" hspace="-1"></font></p><font face="宋体" size="3"><p><font face="宋体" size="3"><br></font></p></font><font face="宋体" size="3"><p align="left">

</p><p style="margin: 0cm 0cm 0pt; line-height: 150%; -ms-layout-grid-mode: char; mso-layout-grid-align: none;"><span lang="EN-US" style="line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast;">8</span><span style="line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast;">月<span lang="EN-US">17</span>日，由我院主办的国家<span lang="EN-US">“</span>十三五<span lang="EN-US">”</span>科技重大专项暨治疗眼底病<span lang="EN-US">1</span>类新药“重组全人源抗<span lang="EN-US">VEGF-</span>抗补体双特异性抗体（<span lang="EN-US">IBI302</span>）”的临床及产业化研究项目启动会举行。新药专项实施管理办公室、市科委有关领导及项目组人员出席启动会。</span></p><p align="left">

</p><p style="margin: 0cm 0cm 0pt; line-height: 150%; -ms-layout-grid-mode: char; mso-layout-grid-align: none;"><span style="color: black; line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-themecolor: text1;">年龄相关性黄斑变性（<span lang="EN-US">AMD</span>）是中国和全球难可逆盲主要病因，已成为老龄化社会重大公共卫生问题。在全球范围内约有<span lang="EN-US">1.7</span>亿的<span lang="EN-US">AMD</span>患者，每年还会新增<span lang="EN-US">30</span>万人。目前，以血管内皮生长因子<span lang="EN-US">(VEGF)</span>为靶点的抗体类药物在新生血管性黄斑变性中已取得突破进展，全球市场总量达<span lang="EN-US">150</span>亿美元以上。</span></p><p align="left">

</p><p style="margin: 0cm 0cm 0pt; line-height: 150%; -ms-layout-grid-mode: char; mso-layout-grid-align: none;"><span style="color: black; line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-themecolor: text1;">然而，单一抗<span lang="EN-US">VEGF</span>治疗方案不仅需要终身治疗，而且</span><span style="line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast;">远期疗效不甚理想<span style="color: black; mso-themecolor: text1;">，开发</span>全新能改善长期预后的药物迫在眉睫，<span style="color: black; mso-themecolor: text1;">国家“十三五”重大科技专项——“治疗眼底病<span lang="EN-US">1</span>类新药重组全人源抗<span lang="EN-US">VEGF-</span>抗补体双特异性抗体的临床及产业化研究”项目（以下简称<span lang="EN-US">IBI302</span>项目）是目前国际该治疗领域首个双特异性靶点药，</span>将成熟的抗</span><span lang="EN-US" style='line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: "Times New Roman";'>VEGF</span><span style="line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast;">与抗致病补体激活相结合，有望成为多种炎症相关眼底病治疗的新方案。</span></p><p align="left">

</p><p style="margin: 0cm 0cm 0pt; line-height: 150%; -ms-layout-grid-mode: char; mso-layout-grid-align: none;"><span lang="EN-US" style="color: black; line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-themecolor: text1;">&nbsp;</span></p><p style="margin: 0cm 0cm 0pt; line-height: 150%; -ms-layout-grid-mode: char; mso-layout-grid-align: none;"><b style="mso-bidi-font-weight: normal;"><span style="background: white; color: #191919; line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: Arial;">关于<span lang="EN-US">IBI302</span>药物</span></b></p><p align="left">

</p><p style="margin: 0cm 0cm 0pt; line-height: 150%; -ms-layout-grid-mode: char; mso-layout-grid-align: none;"><span lang="EN-US" style="color: black; line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-themecolor: text1;"><span style="mso-spacerun: yes;">&nbsp;</span></span><span style="color: black; line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-themecolor: text1;">“重组全人源抗<span lang="EN-US">VEGF-</span>抗补体双特异性抗体”（<span lang="EN-US">IBI302</span>）是信达生物自主研发的治疗眼底病药物，属国际首创抗<span lang="EN-US">VEGF-</span>抗补体双靶点药物，其具备</span><span style="line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast;">全人源、安全性高的特点，不仅能增强原有新生血管病变抑制效果，更可通过抑制慢性炎症减少</span><span lang="EN-US" style='line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: "Times New Roman";'>VEGF</span><span style="line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast;">再分泌和眼部</span><span style='line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: "Times New Roman";'>“</span><span style="line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast;">视网膜组织纤维化</span><span style='line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: "Times New Roman";'>”，</span><span style="line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast;">有望改善患者长期预后<span style="color: black; mso-themecolor: text1;">。目前已完成<span lang="EN-US">IBI302</span>临床前研究，获得药物临床试验批件（<span lang="EN-US">2016L10596</span>）。</span></span></p><p align="left">

</p><p style="margin: 0cm 0cm 0pt; line-height: 150%; -ms-layout-grid-mode: char; mso-layout-grid-align: none;"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="background: white; color: #191919; line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: Arial;">&nbsp;</span></b></p><p style="margin: 0cm 0cm 0pt; line-height: 150%; -ms-layout-grid-mode: char; mso-layout-grid-align: none;"><b style="mso-bidi-font-weight: normal;"><span style="color: black; line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-themecolor: text1;">关于<span lang="EN-US">IBI302</span>项目</span></b></p><p align="left">

</p><p style="margin: 0cm 0cm 0pt; text-align: justify; line-height: 150%; -ms-layout-grid-mode: char; -ms-text-justify: inter-ideograph;"><span style='color: black; font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-themecolor: text1; mso-bidi-font-family: "Times New Roman"; mso-bidi-theme-font: minor-bidi;'>本课题由交通大学附属人民医院眼科孙晓东教授牵头组织实施新药临床试验，信达生物制药<span lang="EN-US">(</span>苏州<span lang="EN-US">)</span>有限公司负责产业化和工艺优化，中国人民解放军广州军区武汉总医院参与临床试验。课题组在前期获得国家<span lang="EN-US">“</span>十二五<span lang="EN-US">”</span>重大新药创制平台专项基础上，构建了眼底病新药研发<span lang="EN-US">-</span>临床研究<span lang="EN-US">-</span>产业化联合创新体系，眼用抗体药物临床研究评价达到国际标准，并已完成产业化建设。本课题拟开展<span lang="EN-US">IBI302</span>的<span lang="EN-US">I-III</span>期药物临床试验，</span><span style="font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast;">完成安全性和疗效初步验证，完善评价标准，并完成上市工艺优化、技术转移及<span lang="EN-US">GMP</span>工艺验证，最终申报国家生物<span lang="EN-US">1</span>类新药证书，递交<span lang="EN-US">BLA</span>。</span></p><p align="left">

</p><p style="margin: 0cm 0cm 0pt; text-align: justify; line-height: 150%; -ms-layout-grid-mode: char; -ms-text-justify: inter-ideograph;"><span lang="EN-US" style="color: black; font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-themecolor: text1;">&nbsp;</span></p><p style="margin: 0cm 0cm 0pt; text-align: justify; line-height: 150%; -ms-layout-grid-mode: char; -ms-text-justify: inter-ideograph;"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="background: white; color: #191919; font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: Arial;">IBI302</span></b><b style="mso-bidi-font-weight: normal;"><span style="background: white; color: #191919; font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: Arial;">项目意义</span></b></p><p align="left">

</p><p style="margin: 0cm 0cm 0pt; line-height: 150%; -ms-layout-grid-mode: char; mso-layout-grid-align: none;"><span lang="EN-US" style="color: black; line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-themecolor: text1;">IBI302</span><span style="color: black; line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-themecolor: text1;">项目作为实现国家“十三五”专项目标的实践者，以提高我国自主创制药物的研发与产业化能力为目标，构建眼底病新药研发<span lang="EN-US">-</span>临床研究<span lang="EN-US">-</span>产业化联合创新体系，具有<b style="mso-bidi-font-weight: normal;">促进生物医药的创新成果转化</b>的重大意义。</span></p><p align="left">

</p><p style="margin: 0cm 0cm 0pt; line-height: 150%; -ms-layout-grid-mode: char; mso-layout-grid-align: none;"><span style="color: black; line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-themecolor: text1;">此外，既往<span lang="EN-US">AMD</span>临床研究中多是以视力和中心视网膜厚度作为疗效的主要评价指标，随着对疾病认识的加深，以上指标并无法反映治疗的长期效果。本课题拟从发病机制出发，<b style="mso-bidi-font-weight: normal;">构建全新的疗效评价标准</b>，通过抑制补体系统激活，探索是否能够以上游<span lang="EN-US">VEGF</span>分泌的降低、<span lang="EN-US">CNV</span>纤维化疤痕化的延缓、地图样萎缩发生的减少及对感光细胞的保护，作为改善患者长期预后的评价指标。</span></p><p align="left">

<p><p><font face="宋体" size="3"><br></font></p><p></p><p></p></font><font face="宋体" size="3"><b style="mso-bidi-font-weight: normal;"><span style="background: white; color: #191919; line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: Arial;">课题负责人<span lang="EN-US">—</span>孙晓东</span></b></font><p></p><p><font face="宋体" size="3">

<span style="color: black; line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: 宋体; mso-font-kerning: 0pt;"><img alt="" src="/front/../upload/images/201808/29084709.jpg" border="0" vspace="0" hspace="-1"></span></font></p><p><font face="宋体" size="3"><span style="color: black; line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: 宋体; mso-font-kerning: 0pt;">孙晓东，交通大学教授，教育部<span lang="EN-US">“</span>长江学者<span lang="EN-US">”</span>特聘教授，国家杰出青年科学基金获得者。主要从事眼底病新药开发及临床基础研究。现任职于交通大学附属人民医院，创建市眼视觉工程技术研究中心。作为国家<span lang="EN-US">“</span>十二五<span lang="EN-US">”</span>重大新药创制专项课题骨干，负责建立眼底病新药创制临床评价研究中心。作为负责人，承担国家<span lang="EN-US">“</span>十三五<span lang="EN-US">”</span>重大新药创制专项、国家<span lang="EN-US">863</span>重点、<span lang="EN-US">973</span>课题、国家杰出青年科学基金等<span lang="EN-US">8</span>项国家级课题。在国内首批开展抗<span lang="EN-US">VEGF</span>抗体治疗，担任<span lang="EN-US">2</span>项抗<span lang="EN-US">VEGF</span>抗体<span lang="EN-US">I</span>期临床试验<span lang="EN-US">PI</span>和<span lang="EN-US">6</span>项抗<span lang="EN-US">VEGF</span>药物多中心临床研究<span lang="EN-US">PI</span>和主要研究者；发表相关论文<span lang="EN-US">122</span>篇，作为大会主席、大会秘书、成功举办<span lang="EN-US">5</span>届<span lang="EN-US">“</span>眼科临床试验国际研讨会<span lang="EN-US">”</span>，多次受邀担任国际眼科新生血管高峰会议<span lang="EN-US">“Angiogenesis”</span>特邀演讲嘉宾。</span></font></p><p><font face="宋体" size="3"><span style="color: black; line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: 宋体; mso-font-kerning: 0pt;"><font face="宋体" size="3"><span style="color: black; line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: 宋体; mso-font-kerning: 0pt;"><font face="宋体" size="3"><span style="color: black; line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: 宋体; mso-font-kerning: 0pt;"><br>市人民医院眼科临床医学中心</span></font></span></font></span></font></p><p><font face="宋体" size="3"><span style="color: black; line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: 宋体; mso-font-kerning: 0pt;"><font face="宋体" size="3"><span style="color: black; line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: 宋体; mso-font-kerning: 0pt;"><font face="宋体" size="3"><span style="color: black; line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: 宋体; mso-font-kerning: 0pt;"><br></span></font></span></font></span></font></p><p><font face="宋体" size="3"><span style="color: black; line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: 宋体; mso-font-kerning: 0pt;"><font face="宋体" size="3"><span style="color: black; line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: 宋体; mso-font-kerning: 0pt;">&nbsp;市人民医院眼科临床医学中心始创于1948年，前身是公济医院眼科，由我国著名的眼科学家、视网膜脱离手术和研究的创始人，人称“东方一只眼”的赵东生教授所创立。是国家临床重点专科、市重中之重临床医学中心、市眼科研究所、市眼底病重点实验室、交通大学眼科研究所、市眼科住院及专科医师培训基地、交通大学眼科学博士点、博士后流动站、交通大学医学院眼科及视觉科学系所在地。历经60年的几代学者的不懈努力，现已建立以“疾病”为中心的团队医学诊疗模式，形成复杂性视网膜脱离、糖尿病视网膜病变、难治性青光眼、复杂性白内障、角膜病及斜弱视等疑难眼病诊治特色。目前眼科已经成为集医、教、研于一体的国内综合性三甲医院中一流的眼科及视觉科学学科。已完成了“十一五”“十二五”国家重点、重大科技支撑项目、国家自然科学基金重点项目等国家及省部级课题52项，获得国家科技进步二等奖、华夏科技奖一等奖、中华医学奖二、三等奖、市科技进步一、二、三等奖等26项，国家专利24项。</span></font></span></font></p><p><font face="宋体" size="3">

</font><p><font face="宋体" size="3"><font face="宋体" size="3"><span style="color: black; line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: 仿宋_GB2312; mso-font-kerning: 0pt;"><strong><br></strong></span></font></font><p align="center"><font face="宋体" size="3"><font face="宋体" size="3"><strong><img alt="" src="/front/../upload/images/201808/29083105.jpg" border="0" vspace="0" hspace="-1"></strong></font></font></p><p align="left"><font face="宋体" size="3"><font face="宋体" size="3"><strong><font face="宋体" size="3"><span style="color: black; line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: 仿宋_GB2312; mso-font-kerning: 0pt;"><font face="宋体" size="3"><span style="color: black; line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: 仿宋_GB2312; mso-font-kerning: 0pt;"><strong><br></strong></span></font></span></font></strong></font></font></p><p align="left"><p><font face="宋体" size="3"><strong><span style="color: black; line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast;"><span lang="EN-US" style="color: black; line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: 仿宋_GB2312; mso-font-kerning: 0pt;"><br></span></span></strong></font></p><p></p><p></p><p></p><p></p><p></p><p><br></p><p><font face="宋体" size="3">

<br></font></p><p style="margin: 0cm 0cm 0pt; line-height: 150%; text-indent: 36pt; mso-layout-grid-align: none; mso-char-indent-count: 3.0;"><span lang="EN-US" style="color: black; line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: 仿宋_GB2312; mso-font-kerning: 0pt;">&nbsp;</span></p><p><font face="宋体" size="3">

<br></font></p><p style="margin: 0cm 0cm 0pt; line-height: 150%; -ms-layout-grid-mode: char; mso-layout-grid-align: none;"><span lang="EN-US" style="color: black; line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: 仿宋_GB2312; mso-font-kerning: 0pt;">&nbsp;</span></p><p><font face="宋体" size="3">

<br></font></p><p style="margin: 0cm 0cm 0pt; line-height: 150%;"><span lang="EN-US" style="color: black; line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: 仿宋_GB2312; mso-font-kerning: 0pt;">&nbsp;</span></p><p><font face="宋体" size="3">

<br></font></p><p style="margin: 0cm 0cm 0pt; line-height: 150%;"><span lang="EN-US" style="color: black; line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-bidi-font-family: 仿宋_GB2312; mso-font-kerning: 0pt;">&nbsp;</span></p><p><font face="宋体" size="3">

<br></font></p><p style="margin: 0cm 0cm 0pt; line-height: 150%;"><span lang="EN-US" style="color: black; line-height: 150%; font-family: 宋体; font-size: 12pt; mso-fareast-font-family: 宋体; mso-ascii-theme-font: minor-fareast; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-fareast; mso-themecolor: text1;">&nbsp;</span></p><p><font face="宋体" size="3">

<br></font></p>
           </div>
     </div>
     <p>&nbsp;</p>
<script language="javascript">
document.title = "我院眼科牵头组织实施国家“十三五”重大创新药IBI302项目临床试验";
</script>
	</div>
    </div>   
    <div class="clear"></div> 
    </div>
    <div class="foot">
      <p>人民医院 版权所有</p>
    </div>
    
</body>
</html>
